LY3325656
DrugAdministered orally
NCT Number: NCT03115099
The aim of this trial is to evaluate the safety of single doses of a study drug known as LY3325656 that is given orally to healthy participants and participants with type 2 diabetes. Information about any side effects that may occur will be collected.
It will also investigate how much of the study drug gets into the blood stream, and how long it takes the body to get rid of it.
The study consists of two parts. Part A will study healthy participants over approximately 12 weeks and Part B will study participants with type 2 diabetes over approximately 5 weeks, excluding screening. Screening is required within 28 days of the start of the study.
Looking for future studies?
Notify Me21 year–70 year
All sexes
Interventional
Phase 1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For all participants:
For participants with Type 2 Diabetes Mellitus:
Exclusion criteria
For all participants:
For participants with Type 2 Diabetes Mellitus:
Administered orally
Administered orally
Administered subcutaneously
Administered orally
Time frame: Baseline through approximately 12 weeks and 5 weeks after first administration of study drug in Parts A and B, respectively
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline up to 72 hours after each dose of study drug
Pharmacokinetics: Area Under the Concentration Curve of LY3325656 From Time Zero to 24 Hours [AUC(0-24)]
Time frame: Baseline up to 72 hours after each dose of study drug
Pharmacokinetics: Maximum Concentration (Cmax) of LY3325656
Eli Lilly and Company
Industry
A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3325656 After Single Dose in Healthy Subjects and Patients With Type 2 Diabetes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05259449
Diabetes Mellitus, Diabetes Mellitus, Type 2
Puerto Real, Cadiz, Spain
View Trial DetailsNCT03899883
Diabetes, Diabetes Complications
Aurora, Colorado, United States
View Trial DetailsNCT07251504
Diabetes Mellitus, Diabetes Mellitus, Type 2
Puerto Real, Cádiz, Spain
View Trial DetailsNCT00445627
Body Weight, Diabetes Mellitus
Bethesda, Maryland, United States
View Trial Details